详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker

63| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Cancer Biology Research Center (Key Laboratory of the Ministry of Education),Tongji Hospital,Huazhong University of Science and Technology,Wuhan,China. [2]GI Cancer Research Institute,Tongji Hospital,Huazhong University of Science and Technology,1095 Jiefang Avenue,Wuhan,China.

出处：

DOI：

ISSN：

关键词： Cervical cancer ctDNA HPV Biomarker

摘要：

Cervical cancer is a leading cause of gynecological cancer death in the world. Human papillomavirus (HPV) is the most causative factor of cervical cancer. In addition, many genetic factors are involved in cervical cancer development. Most studies focus on cervical samples to do research work about cervical cancer and precancerous lesions, but no sensitive or specific biomarkers were found. High-throughput genomic technologies are able to capture information from tumors and precancerous lesions in blood, thus providing a new way for the early diagnosis of cervical precancer and cervical cancer. Blood is an ideal specimen for detecting cancer biomarkers because it contains a lot of information, such as circulating tumor cells and circulating tumor DNA (ctDNA). This article reviews the clinical use and challenges of blood ctDNA testing in patients with cervical precancer and cervical cancer.© 2023. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 5.3 最新[2023版] 5 最新五年平均 6.435 出版当年[2021版] 5.999 出版当年五年平均 5.722 出版前一年[2020版] 5.8 出版后一年[2022版]

第一作者：

第一作者单位： [1]Cancer Biology Research Center (Key Laboratory of the Ministry of Education),Tongji Hospital,Huazhong University of Science and Technology,Wuhan,China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Multi-omics characterization of productive HPV integration in cervical cancer [2]HPV早期蛋白介导病毒免疫逃避的机制 [3]Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women [4]RAB2A promotes cervical cancer progression as revealed by comprehensive analysis of HPV integration and proteome in longitudinal cervical samples [5]不同高危型HPV感染与宫颈癌及宫颈高级别病变的相关性 [6]The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications [7]Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV [8]Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer [9]Long-read sequencing reveals oncogenic mechanism of HPV-human fusion transcripts in cervical cancer [10]HPV-CCDC106 integration promotes cervical cancer progression by facilitating the high expression of CCDC106 after HPV E6 splicing